Source comparison
Ipamorelin Safety Profile: Comparison Table
The following table compares the ipamorelin safety profile to other commonly researched growth hormone secretagogues, highlighting receptor selectivity, adverse event rates, and cortisol impact—the three variables that define peptide safety in endocrine resear
This comparison does not assign a generated winner or score.
- The following table compares the ipamorelin safety profile to other commonly researched growth hormone secretagogues, highlighting receptor selectivity, adverse event rates, and cortisol impact—the three variables that define peptide safety in endocrine research protocols.
- Ipamorelin
- 2–4× baseline at 1.0 mcg/kg
- None (within physiological range)
- None
- Injection-site erythema (6%), transient flushing (4%)
- High—selective GHS-R1a agonist
- Cleanest safety profile; narrow therapeutic window requires precise dosing
- GHRP-2
- 3–5× baseline at 1.0 mcg/kg
- 20–40% elevation
- Hunger stimulation (15%), water retention (8%)
- Moderate—binds GHS-R1a + some ACTH activation
- Effective but cortisol spike limits use in catabolic-sensitive models
- GHRP-6
- 3–6× baseline at 1.0 mcg/kg
- 30–50% elevation
- Intense hunger (25%), water retention (12%)
- Low—broad ghrelin mimetic
- Strongest GH release but poorest selectivity; not suitable for cortisol-sensitive research
- Hexarelin
- 4–7× baseline at 2.0 mcg/kg
- 40–60% elevation
- Mild suppression
- Tachycardia (10%), cortisol-related fatigue (8%)
- Low—activates multiple pathways
- High efficacy but desensitization occurs rapidly; adverse cortisol effects
- MK-677 (Ibutamoren)
- 2–3× baseline (sustained 24h)
- Water retention (18%), increased appetite (22%)
- High—oral ghrelin mimetic
- Oral convenience; prolonged elevation may reduce pulsatility benefits